THE OBJECTIVE LENS IN CYSTOSCOPY
Transforming bladder cancer care.
Cystotech is on a mission to support clinicians during cystoscopy and contribute to improved care and quality of life for bladder cancer patients. We are deeply committed to developing technology grounded in the realities of everyday practice – prioritizing usability, seamless workflow integration, and meaningful clinical value.
CLINICAL WORKFLOW ENHANCEMENT · REAL-TIME SUPPORT · CLINICIAN REMAINS THE DECISION-MAKER
25%
False positive rate in routine diagnostic cystoscopy – leading to overtreatment.
THE PROBLEM
White-light cystoscopy remains the standard of care, but bladder cancer is difficult to consistently identify during visual assessment.
35%
Of bladder tumors are overlooked during first-line detection.
$12B
Annual cost of bladder cancer care across the EU and US.
HOW CYSTOAID® WORKS
What the human eye can’t see, CystoAID® reveals.
03 · CLINICAIAN-LED
Developed by clinicians
CystoAID® was created from real clinical insight gained through more than a decade of hands-on experience. Designed around the practical challenges of everyday cystoscopy, the product is built to support clinicians in real-world practice.
02 · INTEGRATED
Built for clinical reality
CystoAID® is device-agnostic, plug-and-play, and on-premise – integrating seamlessly with existing 3G-SDI cystoscopy systems without cloud dependency or workflow disruption.
01 · OBJECTIVE
From subjective to objective
Cystoscopy today relies on real-time visual interpretation, where subtle abnormalities may be difficult to identify and characterize in real time.
CystoAID® provides AI-assisted decision support to support clinician evaluation of suspicious urothelial lesions during cystoscopy.
VALUE ADD
Where CystoAID® adds clinical value.
SCENARIO 01
Initial diagnostic cystoscopy
Problem: Visually suspicious findings may be difficult to identify during initial cystoscopy, potentially delaying diagnosis and treatment planning – impacting outcomes and increasing downstream costs.
Value add: CystoAID® aims to reduce the risk of overlooked tumours, enabling earlier detection and more effective treatment pathways.
SCENARIO 02
Surveillance cystoscopy
Problem: The risk of bladder cancer recurrence requires long-term surveillance, with cystoscopy typically repeated at risk-adapted intervals from every 3 months to annually.
Value add: CystoAID® supports consistent, objective detection across surveillance procedures, aiming to reduce the risk of missed recurrence and the burden of late-stage re-treatment.
SCENARIO 03
TURBT and intraoperative use
Problem: Incomplete resection is a recognized contributor to early recurrence in non-muscle-invasive bladder cancer.
Value add: CystoAID® supports real-time visual confirmation during tumour removal, aiming to improve resection completeness. The goal is to reduce the need for re-TURBT, lower readmission rates, and decrease overall procedural costs.
SCENARIO 04
Meeting growing demand
Problem: Bladder cancer is a significant and growing global health burden. With increasing demand for urologic evaluation and ongoing pressure on specialist capacity, clinicians need tools that can support efficient, high-quality cystoscopy workflows
Value add: CystoAID® supports consistent decision-making across procedures, helping maintain quality under increasing clinical pressure and a growing caseload.
“ Missed lesions during cystoscopy remain one of the most consequential and underappreciated challenges in bladder cancer care. Real-time AI-assisted detection represents a meaningful step toward closing that gap and ultimately improving outcomes for our patients.
Ashish M. Kamat, MD · Professor of Urology
PRESIDENT INTERNATIONAL BLADDER GROUP
EVIDENCE
The evidence speaks for itself.
CystoAID® has been validated on 437,244 frames across 71 real-world procedures. In non-inferiority testing against white-light cystoscopy, it achieved 88.1% positive predictive value.
RAISE01 · 2024 RWD STUDY · 71 PROCEDURES · 437,244 FRAMES · NON-INFERIORITY DESIGN
→ RAISE02 – Awaiting publication H1 2026
→ RAISE03 – Enrollment H2 2026
66%
of urologists surveyed would definitely or probably use it
88.1%
Positive Predictive Value. Fewer false positives
Results from RAISE01 2024 study
2023 survey of 100 US urologists
“ We are not just improving detection – we are enabling better decisions, in real time, during the procedure itself.
Jacob Elmose Jensen, MD · Chief Medical Officer, Co-Founder
CERTIFIED UROLOGIST
Upcoming events & congresses.
WHERE TO MEET US